A biomarker study of soluble immune markers in stage II-IIIA non-small cell lung cancer (WJOG12319LTR)

A biomarker study of soluble immune markers in stage II-IIIA non-small cell lung cancer (WJOG12319LTR) - A soluble immune biomarker study in resectable non-small cell lung cancer (WJOG12319LTR)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037723

Enrollment

200

Registered

2019-08-26

Start date

2019-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Resectable stage II-IIIA non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients enrolled in WJOG4107 study who had available plasma samples

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Association of soluble immune markers, including soluble PD-L1, soluble PD-1, soluble CTLA-4, and relapse-free survival / overall survival in resectable stage II-IIIA NSCLC	—

Secondary

Measure	Time frame
Association of soluble immune markers, including soluble PD-L1, soluble PD-1, soluble CTLA-4, and clinical background / characteristics	—

Countries

Japan

Contacts

Public ContactShinichiro Nakamura

West Japan Oncology Group WJOG datacenter

datacenter@wjog.jp06-6633-7400

Outcome results